Skip to main content
Equibles
IBIO logo

IBIO · iBio, Inc.

Track IBIO — free

Use IBIO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IBIO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.46 +0.03 (+2.10%)
Going-concern doubt — cleared May 12, 2026

The latest filing states the doubt was alleviated.

“The history of significant losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations in the past raised substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed May 12, 2026
Market Cap
$71.04M
Shares
49.68M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.43 Open$1.38 Day$1.34–1.44 52W close$0.68–3.07 Avg vol 30d706K Short int5.1M · 10.3% float · 7.0d Short vol54% Last earningsSep 27, 2022 DataNov 2023–Aug 2026 Filing10-Q · May 12

Raw chart and full-history price indicators begin at the captured split on Nov 29, 2023; bars on opposite sides are not compared.

Up next

FQ1-27 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 12, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −22%
below
Price vs 50-day avg −7%
below
RSI (14) 47
neutral
MACD trend Positive
52-week position 31%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +4%
trailing
6-month return −42%
trailing
YTD return −26%
this year
Relative strength −55%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.28% of float · ▼ -5.2% MoM · 7.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
56 holders — near 3-yr high, broad support
Squeeze score 63
elevated · 0–100
Fundamentals
Fair
Revenue growth −100%
Y/Y
EPS growth +73%
Y/Y
Free cash flow $-15.3M
Balance sheet $8.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 111%
annualized · 1-yr
Max drawdown −56%
past year
ATR 6.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−22% Bearish
Price vs 50-day avg
−7% Bearish
RSI (14)
47 Neutral
MACD trend
Positive Bullish
52-week position
31% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.28% of float · ▼ -5.2% MoM · 7.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
56 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 31% Range high $3
vs 200-day avg -22% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IBIO
iBio, Inc.
this stock
$71.04M -25.9% -100.0% — 10.3%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
56
% held
69.9%
Net QoQ
+15.3M sh
Top holder
Affinity Asset Advisors,…
Held Float
View
Held by Funds
Fund positions
10
View
Short & Settlement
Short Interest Falling
Shares short
5.1M
Days to cover
7.0d
Change
-278.8K sh
View
Short Volume
Short vol %
54%
As of
Aug 17, 2026
Short Total
View
Fails to Deliver
FTD shares
5.7K
Value
$7.8K
As of
Jul 23, 2026
View
Off-Exchange
Off-exchange %
49.4%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$400.0K
Net income (FY)
$-18.4M
EPS diluted
$-1.75
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 4, 2026
This year
14
View
Exempt Offerings
Offering
$26.0M
Filed
Jan 22, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

Raw-price comparisons begin at the captured split on Nov 29, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
IBIO +1.4% +3.6% -41.6% +2.1% -25.9%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +1.0% -0.8% -55.4% -1.8% -39.8%
Key facts CIK 1420720 CUSIP 451033708 13F (30d) 59 filings 56 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)